DK0551182T3 - Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe - Google Patents

Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe

Info

Publication number
DK0551182T3
DK0551182T3 DK93300052T DK93300052T DK0551182T3 DK 0551182 T3 DK0551182 T3 DK 0551182T3 DK 93300052 T DK93300052 T DK 93300052T DK 93300052 T DK93300052 T DK 93300052T DK 0551182 T3 DK0551182 T3 DK 0551182T3
Authority
DK
Denmark
Prior art keywords
vascular disease
rapamycin
mycophe
comb
optionally
Prior art date
Application number
DK93300052T
Other languages
English (en)
Inventor
Randall Ellis Morris
Clare Robert Gregory
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Application granted granted Critical
Publication of DK0551182T3 publication Critical patent/DK0551182T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK93300052T 1992-01-09 1993-01-06 Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe DK0551182T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81931492A 1992-01-09 1992-01-09

Publications (1)

Publication Number Publication Date
DK0551182T3 true DK0551182T3 (da) 2000-10-09

Family

ID=25227805

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93300052T DK0551182T3 (da) 1992-01-09 1993-01-06 Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe

Country Status (14)

Country Link
EP (1) EP0551182B1 (da)
JP (1) JP2644955B2 (da)
KR (1) KR100276142B1 (da)
AT (1) ATE194493T1 (da)
AU (1) AU665041B2 (da)
CA (1) CA2086642C (da)
DE (1) DE69328981T2 (da)
DK (1) DK0551182T3 (da)
ES (1) ES2147740T3 (da)
GR (1) GR3034479T3 (da)
LV (1) LV12603B (da)
NZ (1) NZ245630A (da)
PT (1) PT551182E (da)
SG (1) SG47639A1 (da)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
KR100616020B1 (ko) * 1996-03-27 2007-01-31 노파르티스 아게 맥관장애및이종이식술에서의라파마이신유도체의용도
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
IT1289815B1 (it) 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US7208011B2 (en) 2001-08-20 2007-04-24 Conor Medsystems, Inc. Implantable medical device with drug filled holes
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6156373A (en) 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en) 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
DE60133053T2 (de) 2000-10-16 2009-02-26 Conor Medsystems, Inc., Menlo Park Ausdehnbare medizinische Vorrichtung zur Abgabe eines nützlichen Agens
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US7842083B2 (en) 2001-08-20 2010-11-30 Innovational Holdings, Llc. Expandable medical device with improved spatial distribution
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ATE538820T1 (de) 2003-02-21 2012-01-15 Sorin Biomedica Cardio Srl Verfahren zur herstellung eines stents und entsprechender stent
AR045957A1 (es) * 2003-10-03 2005-11-16 Novartis Ag Composicion farmaceutica y combinacion
US7303758B2 (en) 2004-01-20 2007-12-04 Cordis Corporation Local vascular delivery of mycophenolic acid in combination with rapamycin to prevent restenosis following vascular injury
JP2007532187A (ja) 2004-04-06 2007-11-15 サーモディクス,インコーポレイティド 生物活性物質のためのコーティング組成物
USD516723S1 (en) 2004-07-06 2006-03-07 Conor Medsystems, Inc. Stent wall structure
WO2007040249A1 (ja) 2005-10-06 2007-04-12 Kaneka Corporation 生体留置用ステント
US20100063585A1 (en) 2006-07-03 2010-03-11 Hemoteq Ag Manufacture, method and use of active substance-releasing medical products for permanently keeping blood vessels open
ES2393639T3 (es) 2007-01-21 2012-12-26 Hemoteq Ag Producto médico para tratar cierres de conductos corporales y prevención de nuevos cierres
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US8921642B2 (en) 2008-01-11 2014-12-30 Massachusetts Eye And Ear Infirmary Conditional-stop dimerizable caspase transgenic animals
EP2944332B1 (en) 2009-07-10 2016-08-17 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
EP2453938B1 (en) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
EP2611476B1 (en) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
JP6278332B2 (ja) 2013-04-22 2018-02-14 スズキ株式会社 変速機の制御装置

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus

Also Published As

Publication number Publication date
AU3107993A (en) 1993-07-15
JPH069390A (ja) 1994-01-18
KR100276142B1 (ko) 2001-02-01
SG47639A1 (en) 1998-04-17
NZ245630A (en) 1997-07-27
GR3034479T3 (en) 2000-12-29
AU665041B2 (en) 1995-12-14
DE69328981T2 (de) 2000-11-16
EP0551182A1 (en) 1993-07-14
HK1010332A1 (en) 1999-06-17
ES2147740T3 (es) 2000-10-01
CA2086642C (en) 2004-06-15
LV12603B (en) 2001-04-20
JP2644955B2 (ja) 1997-08-25
CA2086642A1 (en) 1993-07-10
DE69328981D1 (de) 2000-08-17
ATE194493T1 (de) 2000-07-15
PT551182E (pt) 2000-12-29
LV12603A (en) 2001-01-20
KR930016102A (ko) 1993-08-26
EP0551182B1 (en) 2000-07-12

Similar Documents

Publication Publication Date Title
DK0551182T3 (da) Fremgangsmåde til behandling af hyperproliferative karsygdomme under anvendelse af rapamycin, eventuelt i komb. med mycophe
PY0101639A (es) Method of treating restenosis with rapamycin
DK0583925T3 (da) Rapamycin til behandling af Crohn's sygdom, ulcerøs colitis og ulcerøs proctitis
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
ATE135226T1 (de) Zusammensetzung enthaltend heparin und rapamycin
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE3851913D1 (de) Superabsorbierende Zusammensetzung und Verfahren.
DE3789425D1 (de) Verfahren zur Kettspannungskontrolle.
DK447489A (da) Metode til stabilisering af blod
DE69307617D1 (de) Verwendung von Kompetitiven NMDA-Rezeptorantagonisten zur Behandlung der Harninkontinenz
DE69431638D1 (de) Automatische Fokusausgleicheinstellvorrichtung und Verfahren
FR2709466B1 (fr) Structure de guide de chaine.
ATE138807T1 (de) 29-demethoxyrapamycin zur induktion der immunosuppression
FI910421A7 (fi) Menetelmä rikin binääristen yhdisteiden käsittelemiseksi
DK234590A (da) Fremgangsmaade til behandling af retrovirusinfektioner
FI963638L (fi) Menetelmiä HIV-1-injektion diagnosoimiseksi ja hoitamiseksi
DE69016416D1 (de) Laserstrahlbehandlungsvorrichtung.
DE3785550D1 (de) Photosensible zusammensetzung mit verbesserter haftung, gegenstaende und verfahren.
DE3669159D1 (de) Triazinderivate, verfahren zur herstellung dieser derivate und herbizide, welche diese derivate als wirksame komponente enthalten.
ES1023268Y (es) Pieza perfeccionada parajuegos de construccion.
DE58906954D1 (de) Wässrige lösung zur oxidation, entkeimung und desodorierung sowie verfahren zur herstellung dieser lösung.
DK224390D0 (da) Apparat til faeldning af mindre traeer
DE68914450D1 (de) Verfahren zur bekämpfung von fichtenborkenkäfern und zusammensetzung dafür.
DE68905602D1 (de) Verfahren zur behandlung von titanstrukturen.
NO881907L (no) Dyse for laserbehandling.